Trials / Completed
CompletedNCT02802345
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 274 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To assess efficacy and safety of concomitant treatment with nintedanib and sildenafil in Idiopathic Pulmonary Fibrosis (IPF) patients with advanced lung function impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | |
| DRUG | Placebo | |
| DRUG | Sildenafil |
Timeline
- Start date
- 2016-06-30
- Primary completion
- 2017-12-19
- Completion
- 2018-04-13
- First posted
- 2016-06-16
- Last updated
- 2019-01-11
- Results posted
- 2019-01-11
Locations
85 sites across 13 countries: United States, Australia, Belgium, Canada, France, Germany, India, Italy, Japan, Mexico, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02802345. Inclusion in this directory is not an endorsement.